PDL BioPharma, Inc Buyback
OLI recorded this information on 9/24/2018
PDL BioPharma, Inc
PDL BioPharma, Inc. ("PDL") (NASDAQ: PDLI) announces its Board of Directors has authorized a new stock repurchase program to acquire up to $100 million of the Company's common stock. Purchases may be made in open-market transactions, in block transactions on or off an exchange, in privately negotiated transactions or by other means as determined by PDL's management and in accordance with the regulations of the Securities and Exchange Commission.
PDL BioPharma is engaged in providing alternative sources of capital through royalty monetizations and debt facilities; acquiring commercial-stage products and launching companies for commercialization of these products; as well as transactions involving late clinical-stage or early commercial-stage therapeutics. Co.'s subsidiary, LENSAR, Inc., is a medical device company focused on delivering femtosecond cataract laser technology used in refractive cataract surgical procedures. Co. also has investment in Evofem Biosciences, Inc., a clinical-stage biopharmaceutical company engaged in developing and commercializing products to address unmet needs in women's sexual and reproductive health.
Open the PDLI Page at The Online Investor »
Free PDLI Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts
Hold (2.00 out of 4)